Black Diamond Therapeutics (BDTX) Free Cash Flow: 2018-2024
Historic Free Cash Flow for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to -$62.3 million.
- Black Diamond Therapeutics' Free Cash Flow fell 53.49% to -$24.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$102.9 million, marking a year-over-year decrease of 96.71%. This contributed to the annual value of -$62.3 million for FY2024, which is 6.66% up from last year.
- As of FY2024, Black Diamond Therapeutics' Free Cash Flow stood at -$62.3 million, which was up 6.66% from -$66.8 million recorded in FY2023.
- In the past 5 years, Black Diamond Therapeutics' Free Cash Flow registered a high of -$52.3 million during FY2020, and its lowest value of -$102.9 million during FY2021.
- Its 3-year average for Free Cash Flow is -$71.4 million, with a median of -$66.8 million in 2023.
- Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 111.74% in 2020, then climbed by 21.72% in 2023.
- Over the past 5 years, Black Diamond Therapeutics' Free Cash Flow (Yearly) stood at -$52.3 million in 2020, then slumped by 96.71% to -$102.9 million in 2021, then grew by 17.10% to -$85.3 million in 2022, then increased by 21.72% to -$66.8 million in 2023, then increased by 6.66% to -$62.3 million in 2024.